^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pegylated liposomal doxorubicin

    i
    Other names: Doxorubicin Hydrochloride Cytori, ATI-0918, Dox-SL, SPI 49, JNS-002, TLC177, TLC 177
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    6d
    Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas (clinicaltrials.gov)
    P2, N=65, Recruiting, University of Colorado, Denver | Trial completion date: Nov 2026 --> Dec 2027 | Trial primary completion date: Nov 2025 --> Apr 2027
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    pegylated liposomal doxorubicin • balstilimab (AGEN2034) • botensilimab (AGEN1181) • zalifrelimab (UGN-301)
    6d
    Exosomes displaying native EGF enhance doxorubicin's therapeutic efficacy and reduce cardiotoxicity. (PubMed, J Nanobiotechnology)
    Our findings demonstrate that tumor-derived exosomes engineered with EGF on their surface enable targeted drug delivery to tumors with high EGFR expression. Although the exosomes modestly increase cell proliferation in vitro, the EGF-Exo-DOX formulation exhibits enhanced tumor accumulation relative to the heart, minimal cardiac uptake, and shows no tumorigenic effects in vivo. Compared to Lipo-DOX, a widely used clinical formulation of liposomal DOX in China, EGF-Exo-DOX demonstrates superior cellular uptake, greater induction of tumor cell apoptosis, and improved anti-tumor efficacy. These results highlight the potential of engineered exosomes as a targeted drug delivery platform for patients with EGFR-overexpressing tumors.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    doxorubicin hydrochloride • pegylated liposomal doxorubicin
    10d
    MAESTRA 2: Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (clinicaltrials.gov)
    P3, N=466, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan
    10d
    Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma (clinicaltrials.gov)
    P3, N=130, Not yet recruiting, AIDS Malignancy Consortium | Trial completion date: Nov 2027 --> Sep 2030 | Trial primary completion date: Dec 2026 --> Sep 2029
    Trial completion date • Trial primary completion date • Head-to-Head
    |
    paclitaxel • pegylated liposomal doxorubicin
    13d
    Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY) (clinicaltrials.gov)
    P2, N=81, Recruiting, National Health Research Institutes, Taiwan | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    pegylated liposomal doxorubicin
    17d
    TREVI-OC-01: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=1100, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • torvutatug samrotecan (AZD5335)
    18d
    Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science. (PubMed, Clin Transl Sci)
    Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate (ADC) composed of the DM4 payload conjugated to a folate receptor α (FRα)-targeting antibody via the cleavable sulfo-SPDB linker. The MIRV Phase 3 registrational trial (MIRASOL) showed superiority of MIRV vs. chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) in patients with high (≥ 75%) FRα-expression PROC, showing an objective response rate of 42% versus 16%, a median progression-free survival of 5.6 versus 4.0 months, and an overall survival of 16.5 versus 12.8 months. Here, we briefly review MIRV mechanism of action, pharmacokinetics, pharmacodynamics, and key clinical efficacy and safety data.
    Review • Journal
    |
    FOLR1 ( Folate receptor alpha ) • PROC (Protein C, Inactivator Of Coagulation Factors Va And VIIIa)
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan
    21d
    REJOICE-Ovarian01: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2/3, N=860, Recruiting, Daiichi Sankyo | Trial completion date: Dec 2029 --> Apr 2030
    Trial completion date • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • topotecan • raludotatug deruxtecan (DS-6000)
    25d
    GOLSEEK-2: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • bendamustine • golcadomide (CC-99282)
    27d
    A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, OHSU Knight Cancer Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 positive • HR positive • HER-2 negative • EGFR positive
    |
    Lynparza (olaparib) • Tagrisso (osimertinib) • carboplatin • gefitinib • gemcitabine • paclitaxel • temozolomide • tamoxifen • Verzenio (abemaciclib) • pemetrexed • fulvestrant • letrozole • pegylated liposomal doxorubicin • exemestane • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • simmitinib (SYHA1817)
    29d
    LETROZOLE IMPROVES PROGRESSION-FREE SURVIVAL OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH PEGYLATED LIPOSOMAL DOXORUBICIN AND MAGNETOTHERMY. (PubMed, Exp Oncol)
    PLD with local MH in combination with letrozole was more effective irrespective of the PIK3CA gene status in postmenopausal aBC patients.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    |
    letrozole • pegylated liposomal doxorubicin
    2ms
    A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, GlaxoSmithKline
    New P3 trial • Platinum resistant
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • mocertatug rezetecan (GSK5733584)